Nathan R Every - Net Worth and Insider Trading

Nathan R Every Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Nathan R Every owns 4 companies in total, including AnaptysBio Inc (ANAB) , Sierra Oncology Inc (SRRA) , and Glaukos Corp (GKOS) among others .

Click here to see the complete history of Nathan R Every’s form 4 insider trades.

Insider Ownership Summary of Nathan R Every

Ticker	Comapny	Transaction Date	Type of Owner
ANAB	AnaptysBio Inc	2017-01-25	10 percent owner
SRRA	Sierra Oncology Inc	2017-02-14	10 percent owner
GKOS	Glaukos Corp	2015-06-24	10 percent owner
		2015-05-06	10 percent owner

Nathan R Every Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Nathan R Every Ownership Network

Ownership Network List of Nathan R Every

No Data

Ownership Network Relation of Nathan R Every

Nathan R Every Owned Company Details

What does AnaptysBio Inc do?

Who are the key executives at AnaptysBio Inc?

Nathan R Every is the 10 percent owner of AnaptysBio Inc. Other key executives at AnaptysBio Inc include 10 percent owner Ecor1 Capital, Llc , Chief Medical Officer Paul F. Lizzul , and General Counsel Eric J Loumeau .

AnaptysBio Inc (ANAB) Insider Trades Summary

Over the past 18 months, Nathan R Every made no insider transaction in AnaptysBio Inc (ANAB). Other recent insider transactions involving AnaptysBio Inc (ANAB) include a net sale of 9,774 shares made by Paul F. Lizzul , a net sale of 20,687 shares made by Eric J Loumeau , and a net sale of 18,965 shares made by Dennis Mulroy .

In summary, during the past 3 months, insiders sold 0 shares of AnaptysBio Inc (ANAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 229,132 shares of AnaptysBio Inc (ANAB) were sold and 359,070 shares were bought by its insiders, resulting in a net purchase of 129,938 shares.

AnaptysBio Inc (ANAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

AnaptysBio Inc Insider Transactions

No Available Data

What does Sierra Oncology Inc do?

Who are the key executives at Sierra Oncology Inc?

Nathan R Every is the 10 percent owner of Sierra Oncology Inc. Other key executives at Sierra Oncology Inc include director & 10 percent owner Vivo Opportunity Fund Holdings, L.p. , Chief Reg & Tech Ops Officer William D. Turner , and General Counsel Mary Christina Thomson .

Sierra Oncology Inc (SRRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sierra Oncology Inc (SRRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sierra Oncology Inc (SRRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sierra Oncology Inc (SRRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sierra Oncology Inc Insider Transactions

No Available Data

What does Glaukos Corp do?

Who are the key executives at Glaukos Corp?

Nathan R Every is the 10 percent owner of Glaukos Corp. Other key executives at Glaukos Corp include SVP & Chief Financial Officer Alex R. Thurman , Chief Development Officer Tomas Navratil , and CFO & SVP Corporate Development Joseph E Gilliam .

Glaukos Corp (GKOS) Insider Trades Summary

Over the past 18 months, Nathan R Every made no insider transaction in Glaukos Corp (GKOS). Other recent insider transactions involving Glaukos Corp (GKOS) include a net sale of 269,958 shares made by Joseph E Gilliam , a net sale of 8,282 shares made by Alex R. Thurman , and a net sale of 41,347 shares made by Gilbert H Kliman .

In summary, during the past 3 months, insiders sold 25,623 shares of Glaukos Corp (GKOS) in total and bought 0 shares, with a net sale of 25,623 shares. During the past 18 months, 733,050 shares of Glaukos Corp (GKOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 733,050 shares.

Glaukos Corp (GKOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Glaukos Corp Insider Transactions

No Available Data

What does Collegium Pharmaceutical Inc do?

Who are the key executives at Collegium Pharmaceutical Inc?

Nathan R Every is the 10 percent owner of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP & Chief Financial Officer Tupper Colleen , EVP & Chief Commercial Officer Scott Dreyer , and EVP and General Counsel Shirley R. Kuhlmann .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Nathan R Every made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 201,056 shares made by Scott Dreyer , a net sale of 184,392 shares made by Shirley R. Kuhlmann , and a net sale of 42,187 shares made by Tupper Colleen .

In summary, during the past 3 months, insiders sold 168,024 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 168,024 shares. During the past 18 months, 539,338 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 539,338 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Collegium Pharmaceutical Inc Insider Transactions

No Available Data

Nathan R Every Mailing Address

Above is the net worth, insider trading, and ownership report for Nathan R Every. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Nathan R Every's mailing address is: Seattle Wa 98101.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.